Mixed Dyslipidemia
📧 Sign up to get email alerts when something new happens for Mixed Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-11-03FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fenofibrate, confirming approval of a generic fenofibrate product.
-
FDA approval · 2014-10-31FDA Approved: FENOFIBRATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic fenofibrate under an Original Application.
-
CLINICAL_TRIALS trial_result · 2014-06-11Clinical Trial Update: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [Phase 4]
Phase 4 trial evaluating the efficacy and safety of fluvastatin sodium extended-release 80 mg once daily in Chinese patients with primary hy…
-
CLINICAL_TRIALS trial_result · 2014-04-25Clinical Trial Update: Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
The Niacin/laropiprant re-examination study (TREDAPTIVE) for hypercholesterolemia and mixed dyslipidemia was terminated, with results posted…
-
FDA approval · 2014-03-20FDA Approved: NIACIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original abbreviated new drug application for NIACIN, a generic nicotinic acid product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-03-14Clinical Trial Update: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) [Phase 3]
Phase 3 trial evaluating MK-0524A (extended-release niacin/laropiprant) added to ongoing lipid-modifying therapy in patients with primary hy…
-
FDA approval · 2013-12-04FDA Approved: FENOFIBRIC ACID — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' original application for fenofibric acid, a lipid-lowering agent indicated for certain lipid disorde…
-
FDA approval · 2013-10-18FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Fenofibrate submitted by Lupin Pharmaceuticals, Inc. This indicates a change or addition to …
-
FDA approval · 2013-08-06FDA Approved: FENOFIBRATE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for fenofibrate from Rhodes Pharmaceuticals L.P., authorizing a new generic version of the drug.
-
FDA approval · 2013-07-26FDA Approved: FENOFIBRATE — Original Application (Apotex Corp.)
The FDA approves the original (ANDA) application for fenofibrate from Apotex Corp., granting generic approval for the lipid-lowering medicin…
-
FDA approval · 2012-11-30FDA Approved: LIPITOR — Supplemental Application (Viatris Specialty LLC)
FDA approved Lipitor (atorvastatin calcium) under a supplemental application submitted by Viatris Specialty LLC.
-
FDA approval · 2012-10-19FDA Approved: FENOFIBRATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC’s supplemental application for fenofibrate, authorizing the generic product's approval.
-
FDA approval · 2012-09-05FDA Approved: FENOFIBRIC ACID — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for fenofibric acid from Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2012-04-30Clinical Trial Update: Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia [Phase 4]
Phase 4 trial comparing pitavastatin 4 mg to pravastatin 40 mg in adults with primary hyperlipidemia or mixed dyslipidemia has completed and…
-
FDA approval · 2012-03-01FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin Pharmaceuticals' supplemental application for fenofibrate.
-
FDA approval · 2012-03-01FDA Approved: FENOFIBRATE — Original Application (Dr. Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories Limited's original application (ANDA090859) for a generic fenofibrate product, authorizing its marketi…
-
FDA approval · 2012-02-28FDA Approved: LESCOL XL — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for LESCOL XL (fluvastatin sodium) filed by Sandoz Inc.
-
FDA approval · 2011-12-01FDA Approved: VYTORIN — Supplemental Application (Organon LLC)
FDA approved a supplemental application for VYTORIN (ezetimibe and simvastatin) by Organon LLC, updating its labeling and indications.
-
CLINICAL_TRIALS trial_result · 2011-11-08Clinical Trial Update: Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia [Phase 3]
Phase 3 trial evaluating the efficacy and safety of fluvastatin in children with heterozygous familial hypercholesterolemia; the study has c…
-
FDA approval · 2011-06-27FDA Approved: FENOFIBRATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for fenofibrate from Amneal Pharmaceuticals NY LLC under the ANDA. The approval confirms changes…
-
FDA approval · 2011-03-14FDA Approved: FENOFIBRIC ACID — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for fenofibric acid submitted by Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2009-12-07Clinical Trial Update: A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia [Phase 3]
This Phase 3 safety-extension trial evaluates ABT-335 in combination with statin therapy for mixed dyslipidemia; results were posted in 2009…
-
CLINICAL_TRIALS trial_result · 2009-11-05Clinical Trial Update: Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood [Phase 3]
Phase 3 safety and efficacy study comparing ABT-335 coadministered with atorvastatin and ezetimibe versus atorvastatin with ezetimibe in sub…
-
CLINICAL_TRIALS trial_result · 2009-07-31Clinical Trial Update: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) [Phase 3]
A Phase 3 study evaluating extended-release niacin with laropiprant for lipid management in adults with primary hypercholesterolemia or mixe…
-
CLINICAL_TRIALS trial_result · 2009-07-23Clinical Trial Update: Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. [Phase 3]
A Phase 3 trial evaluating ABT-335 in combination with three different statins in subjects with mixed dyslipidemia, examining long-term safe…